7 Ohmz

Brand Overview
7 OHMZ, run by Thang Botanicals, Inc., specializes in botanical extracts, specifically high-purity 7-hydroxymitragynine (7-OH), an alkaloid from the kratom plant. They refer to themselves as “Advanced Botanical Extracts.” 7 OHMZ claims to be the first company to bring a pure 7-hydroxymitragynine product to market.

Scientific & Pharmacological Basis
The active ingredient in 7 OHMZ products is 7-hydroxymitragynine, naturally found in kratom in small amounts. Compared to mitragynine, the main kratom alkaloid, 7-OH is significantly more potent. The brand states that 7-OH binds strongly to opioid receptors, contributing to its pain-relieving effects. 7 OHMZ also emphasizes proprietary extraction techniques that isolate 7-OH while minimizing other alkaloids, resulting in a high-purity product.

Quality Assurance & Manufacturing
7 OHMZ asserts that each batch undergoes thorough testing for potency, microbial contamination, and purity, conducted by an ISO-certified third-party laboratory. Their production process emphasizes precision and consistency, including thorough mixing, the use of accurate equipment, and high-quality tablet pressing machinery to ensure uniformity. Certificates of Analysis (COAs) are provided for each batch, highlighting transparency in quality control and product reliability.

Product Portfolio
While 7 OHMZ primarily focuses on 7-OH, they offer a variety of product formats through affiliates and resellers:

• Tablets: 14 mg 7-OH tablets are the flagship product.

• Shots / Liquid: Potent liquid formulations, including products like “Tropic Thunder” kratom shots.

• Gummies: 7-OH gummies, with flavors such as Strawberry Acai.

• Other Extracts: Certain resellers, such as 7OH+, also offer full-spectrum kratom extracts from 7 OHMZ.

Regulatory Status & Risks
Regulatory compliance is a critical aspect of 7 OHMZ’s operations.

FDA Warning Letter
On June 25, 2025, the FDA issued a warning letter to Thang Botanicals regarding their 14 mg 7-OH tablets, kratom shots, and 7-OH gummies. Key concerns included:

• 7-OH has not been evaluated for safety in these products.

• Marketing as food or dietary supplements is not authorized.

• 7-OH exhibits opioid-like effects, raising safety concerns.

Food/Additive Classification
The FDA considers 7-OH (or kratom extracts standardized for 7-OH) a “food additive” when included in conventional foods like gummies. Since it has not received premarket approval and is not Generally Recognized As Safe (GRAS), these products are considered adulterated.

New Dietary Ingredient (NDI) Issue
7-OH is regarded as a new dietary ingredient in supplements, but insufficient safety data exists. Therefore, supplements containing 7-OH are considered adulterated under FDA regulations.

Public Health Risks
The FDA reports that 7-OH products have been associated with addiction, seizures, withdrawal symptoms, gastrointestinal issues, and other adverse reactions. The agency advises consumers to avoid 7-OH products, as they are potent opioid-like compounds that have not been proven safe or effective.

Scheduling Recommendation
In July 2025, the FDA recommended stricter regulatory control under the Controlled Substances Act (CSA), citing potential abuse risks. This represents a significant business risk for 7 OHMZ if implemented.

Strengths & Competitive Advantages

• Early Market Presence: One of the first brands to focus on 7-hydroxymitragynine, giving a first-mover advantage.

• High Purity Extraction: Isolation of 7-OH with minimal other alkaloids appeals to users seeking potent, specific effects.

• Robust Quality Control: Batch testing, COAs, and third-party lab verification foster consumer trust.

• Versatile Formats: Tablets, gummies, and liquids cater to diverse consumer preferences and use cases.

Challenges & Risks

• Regulatory Scrutiny: FDA warnings pose potential restrictions, product reformulation, or bans.

• Safety Concerns: 7-OH’s opioid-like potency carries risks of misuse, dependence, and adverse health effects.

• Reputation: Regulatory attention could affect brand image and business partnerships.

• Sustainability: Potential scheduling as a controlled substance could impact market viability.

• Legal Liability: Risk of lawsuits if adverse events or misuse occur, given the potency of the products.

Strategic Implications & Outlook

• Regulatory Compliance: Responding to FDA concerns, conducting safety studies, and obtaining necessary approvals are essential.

• Consumer Education: Clear guidance on risks, safe usage, and addiction potential will support responsible growth.

• Product Diversification: Exploring other botanical extracts could reduce dependence on 7-OH.

• Research Partnerships: Collaborations with scientific institutions could provide safety and efficacy data, enhancing regulatory legitimacy.

• Maintaining Quality Standards: Ongoing rigorous quality control will differentiate the brand as competitors enter the market.

Conclusion
7 OHMZ is a prominent brand in the kratom alkaloid market, with a clear focus on 7-hydroxymitragynine. Their emphasis on purity, product consistency, and innovation provides competitive advantages. However, regulatory challenges, safety concerns, and potential scheduling as a controlled substance pose substantial risks. The company’s ability to navigate compliance, maintain product quality, and educate consumers will be decisive in sustaining its market position.